Drug Search Results
More Filters [+]

Duligotuzumab

Alternative Names: duligotuzumab
Latest Update: 2022-09-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ERBB3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duligotuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Head and Neck Cancer|Squamous Cell Carcinoma|Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R/M SCCHN

P1

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2017-06-22

GO29030

P1

Completed

Sarcoma

2016-01-01

Recent News Events